287 related articles for article (PubMed ID: 33030817)
1. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome.
Körtvelyessy P; Kuhle J; Düzel E; Vielhaber S; Schmidt C; Heinius A; Leypoldt F; Schraven B; Reinhold D; Leppert D; Goihl A
Ann Clin Transl Neurol; 2020 Nov; 7(11):2213-2220. PubMed ID: 33030817
[TBL] [Abstract][Full Text] [Related]
2. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.
Altmann P; De Simoni D; Kaider A; Ludwig B; Rath J; Leutmezer F; Zimprich F; Hoeftberger R; Lunn MP; Heslegrave A; Berger T; Zetterberg H; Rommer PS
J Neuroinflammation; 2020 Mar; 17(1):86. PubMed ID: 32183837
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.
Kmezic I; Samuelsson K; Finn A; Upate Z; Blennow K; Zetterberg H; Press R
Eur J Neurol; 2022 Sep; 29(9):2810-2822. PubMed ID: 35638376
[TBL] [Abstract][Full Text] [Related]
4. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.
Gaiottino J; Norgren N; Dobson R; Topping J; Nissim A; Malaspina A; Bestwick JP; Monsch AU; Regeniter A; Lindberg RL; Kappos L; Leppert D; Petzold A; Giovannoni G; Kuhle J
PLoS One; 2013; 8(9):e75091. PubMed ID: 24073237
[TBL] [Abstract][Full Text] [Related]
5. Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus.
Tyrberg T; Nilsson S; Blennow K; Zetterberg H; Grahn A
J Neurovirol; 2020 Oct; 26(5):719-726. PubMed ID: 32816287
[TBL] [Abstract][Full Text] [Related]
6. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome.
Dujmovic I; Lunn MP; Reilly MM; Petzold A
Muscle Nerve; 2013 Jul; 48(1):132-4. PubMed ID: 23716297
[TBL] [Abstract][Full Text] [Related]
7. Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
Keddie S; Smyth D; Keh RYS; Chou MKL; Grant D; Surana S; Heslegrave A; Zetterberg H; Wieske L; Michael M; Eftimov F; Bellanti R; Rinaldi S; Hart MS; Petzold A; Lunn MP
Brain; 2023 Nov; 146(11):4562-4573. PubMed ID: 37435933
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study.
Axelsson M; Sjögren M; Andersen O; Blennow K; Zetterberg H; Lycke J
Acta Neurol Scand; 2018 Aug; 138(2):143-150. PubMed ID: 29624650
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome.
Wang XK; Zhang HL; Meng FH; Chang M; Wang YZ; Jin T; Mix E; Zhu J
Neurol Sci; 2013 May; 34(5):655-61. PubMed ID: 22526766
[TBL] [Abstract][Full Text] [Related]
10. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.
Mariotto S; Gajofatto A; Zuliani L; Zoccarato M; Gastaldi M; Franciotta D; Cantalupo G; Piardi F; Polo A; Alberti D; Sartori S; Zanusso G; Agrò L; Demurtas R; Sechi G; Sechi E; Monaco S; Ferrari S
J Neurol; 2019 Jul; 266(7):1643-1648. PubMed ID: 30944980
[TBL] [Abstract][Full Text] [Related]
11. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies.
Mariotto S; Farinazzo A; Magliozzi R; Alberti D; Monaco S; Ferrari S
J Peripher Nerv Syst; 2018 Sep; 23(3):174-177. PubMed ID: 29974556
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
[TBL] [Abstract][Full Text] [Related]
13. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.
Martín-Aguilar L; Camps-Renom P; Lleixà C; Pascual-Goñi E; Díaz-Manera J; Rojas-García R; De Luna N; Gallardo E; Cortés-Vicente E; Muñoz L; Alcolea D; Lleó A; Casasnovas C; Homedes C; Gutiérrez-Gutiérrez G; Jimeno-Montero MC; Berciano J; Sedano-Tous MJ; García-Sobrino T; Pardo-Fernández J; Márquez-Infante C; Rojas-Marcos I; Jericó-Pascual I; Martínez-Hernández E; Morís de la Tassa G; Domínguez-González C; Illa I; Querol L
J Neurol Neurosurg Psychiatry; 2020 Nov; ():. PubMed ID: 33154183
[TBL] [Abstract][Full Text] [Related]
14. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
Wong YYM; Bruijstens AL; Barro C; Michalak Z; Melief MJ; Wierenga AF; van Pelt ED; Neuteboom RF; Kuhle J; Hintzen RQ
Neurology; 2019 Sep; 93(10):e968-e974. PubMed ID: 31383792
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis.
Le ND; Muri L; Grandgirard D; Kuhle J; Leppert D; Leib SL
J Neuroinflammation; 2020 Oct; 17(1):293. PubMed ID: 33028339
[TBL] [Abstract][Full Text] [Related]
16. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome.
Petzold A; Brettschneider J; Jin K; Keir G; Murray NM; Hirsch NP; Itoyama Y; Reilly MM; Takeda A; Tumani H
Muscle Nerve; 2009 Jul; 40(1):42-9. PubMed ID: 19533642
[TBL] [Abstract][Full Text] [Related]
17. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
18. Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease.
Wang X; Qu Y; Fan J; Ren H
Front Immunol; 2024; 15():1388734. PubMed ID: 38807603
[TBL] [Abstract][Full Text] [Related]
19. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
